

## **SWIXX AND VIFOR PHARMA SIGN FERINJECT® DISTRIBUTION DEAL FOR SLOVAKIA**

**SWIXX ANNOUNCEMENT NO. 29**

**March 25th, 2020**

**Baar, Switzerland** – Swixx BioPharma AG announced today the signing of a Distribution and Promotion Agreement with Vifor Pharma Group of St. Gallen, Switzerland. The contract gives Swixx the right to commercialize (market, sell and distribute) Vifor Pharma’s high dose i.v. iron product, Ferinject®, in Slovakia. Ferinject® is a solution of ferric carboxymaltose used for high dose intravenous treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. Ferinject® enjoys a premium position in the market due to a track record of delivering exceptional patient value as a high dose i.v. iron which is consistently proven to be both safe and effective.

“It’s an honour for Swixx to be chosen by Vifor Pharma as partner to commercialize Ferinject® in Slovakia,” commented Swixx CEO Jean-Michel Lespinasse. “Ferinject® is the leading high dose i.v. iron globally,” continued Lespinasse, “It’s exciting for us to have the opportunity to work with such a fine product as Ferinject®, with its potential to better the lives of patients across many therapeutic categories in medicine.”

Swixx’s General Manager in Slovakia, Dr. Gabriela Markovova, also expressed her delight at the opportunity to work with Ferinject®. “Our team here at Swixx Slovakia, working both with our colleagues at Vifor Pharma and with the Slovak medical community, hope to increase access to this important treatment for Slovak patients. Further, we see an excellent synergy between Ferinject® and Swixx’s other products in gastroenterology, oncology and obstetrics and gynaecology.”

### **About Swixx BioPharma AG**

Swixx now operates fully-owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. With 350 employees and sales exceeding 200M Euros in 2020, Swixx is now the largest and fastest-growing dedicated agent for biopharma in CEE. The company has gathered outstanding specialty pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. For more info about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

### **About Vifor Pharma Group**

Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care);

and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit [viforpharma.com](http://viforpharma.com).

**Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.**

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

**Note on Unsubscribing from Swixx Announcement Mailing List:** *In accordance with the GDPR (General Data Protection Regulation) provisos of the EU, should you wish to unsubscribe / opt out of our mailing list, please send to [Maja.Boskovic@swixxbiopharma.com](mailto:Maja.Boskovic@swixxbiopharma.com) a one-line message „Please unsubscribe me.“*